The metastasis-associated gene MTA3 is an independent prognostic parameter in uterine non-endometrioid carcinomas

Histopathology

Volumn 60, Issue 4, 2012, Pages 665-670

  Mylonas, Ioannis ^a   Brüning, Ansgar ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; CANCER GROWTH; CANCER STAGING; CAUSE SPECIFIC SURVIVAL; COMORBIDITY; DEACETYLATION; DOWN REGULATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FOLLOW UP; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LYMPH NODE METASTASIS; METASTASIS ASSOCIATED GENE MTA3; OBESITY; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; TUMOR GENE; UPREGULATION; UTERUS CARCINOMA;

AGED; CARCINOMA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; UTERINE NEOPLASMS; UTERUS;

EID: 84857369944     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04103.x     Document Type: Letter

References (11)

1. Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin. Exp. Metast. 2009; 26; 215-227.
2. Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003; 113; 207-219.
3. Dannenmann C, Shabani N, Friese K, Jeschke U, Mylonas I, Brüning A. The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biol. Ther. 2008; 7; 1460-1467.
4. Brüning A, Jückstock J, Blankenstein T, Makovitzky J, Kunze S, Mylonas I. The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas. Histol. Histopathol. 2010; 25; 1447-1456.
5. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005; 366; 491-505.
6. Prat J. Prognostic parameters of endometrial carcinoma. Hum. Pathol. 2004; 35; 649-662.
7. Shabani N, Kuhn C, Kunze S et al. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur. J. Cancer 2007; 43; 2434-2444.
8. Mylonas I, Worbs S, Shabani N et al. Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur. J. Cancer 2009; 45; 1304-1314.
9. Mylonas I. Inhibin-alpha, -betaA and -betaB subunits in uterine non-endometrioid carcinomas: prognostic significance and clinical implications. Eur. J. Cancer 2010; 46; 2485-2493.
10. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet. 2009; 105; 103-104.
11. Bruning A, Makovitzky J, Gingelmaier A, Friese K, Mylonas I. The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells. Histochem. Cell Biol. 2009; 132; 33-38.